Literature DB >> 28924131

Takotsubo-like Myocardial Dysfunction in a Patient with Botulism.

Shuichi Tonomura1, Yoshiaki Kakehi1, Masatoshi Sato2, Yuki Naito1, Hisao Shimizu1, Yasunobu Goto3, Nobuyuki Takahashi1.   

Abstract

Botulinum toxin A (BTXA) can disrupt the neuromuscular and autonomic functions. We herein report a case of autonomic system dysfunction that manifested as Takotsubo-like myocardial dysfunction in a patient with botulism. Takotsubo syndrome results in acute cardiac insufficiency, another fatal complication of botulism in addition to respiratory muscle paralysis, particularly in patients with cardiovascular disease.

Entities:  

Keywords:  Takotsubo syndrome; autonomic failure; botulinum toxin A; botulism

Mesh:

Substances:

Year:  2017        PMID: 28924131      PMCID: PMC5709640          DOI: 10.2169/internalmedicine.8968-17

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Botulism is usually caused by the ingestion of toxins produced by the spore-forming obligate anaerobic bacillus Clostridium botulinum. Improved food sanitation control over the past several decades has reduced the incidence of food-borne botulism in Japan. There are five botulinum toxins, designated A to G. Botulinum toxin type A (BTXA) prevents acetylcholine release from the presynaptic membrane by cleaving a 25-kDa synaptosomal-associated protein at neuromuscular junctions, postganglionic parasympathetic nerve endings, and peripheral ganglia, resulting in motor and autonomic paralysis (1). Clinically, the most critical symptom of botulism is dyspnea due to respiratory muscle paralysis. Autonomic symptoms, blurred vision, dry mouth, orthostatic hypotension, and constipation are other typical symptoms but are regarded as non-fatal. Takotsubo syndrome, an acute reversible apical ventricular dysfunction caused by sympathetic neuronal and catecholamine surge (2), can result in acute cardiac insufficiency, particularly in patients with a history of cardiovascular disease. We herein report the first case of BTXA toxicity resulting in Takotsubo-like myocardial dysfunction due to autonomic failure. The patient's written consent for the publication of this article was obtained, and any information, including illustrations, have been anonymized as far as possible.

Case Report

A 63-year-old man with a history of aortic valve replacement with an artificial heart valve for aortic stenosis presented to the emergency department with nausea, vomiting, blurred vision, and xerostomia a few days after he had eaten an insufficiently cooked instant meal (cooked in a sealed plastic pouch). An initial neurological examination revealed only bilateral ptosis and hoarseness; however, hypoxic respiratory failure, increased blood pressure, and tachycardia occurred within a few hours. After incubation and respiratory assistance, chest X-ray revealed aspiration pneumonia and cardiogenic collapse. Two-dimensional echocardiograms revealed apical ballooning without myocardial infarction, findings consistent with Takotsubo syndrome (Figure A, B).
Figure.

Two-dimensional echocardiogram. Two chamber view of the left ventricle during diastole (A) and systole (B) showing akinetic and balloon apex in systolic (*) and alternatively normal contractile base (†), consistent with the findings in Takotsubo syndrome. After 14 days, wall motion normalized in diastolic (C) and systolic (D) phases. Two-dimensional echocardiogram.

Two-dimensional echocardiogram. Two chamber view of the left ventricle during diastole (A) and systole (B) showing akinetic and balloon apex in systolic (*) and alternatively normal contractile base (†), consistent with the findings in Takotsubo syndrome. After 14 days, wall motion normalized in diastolic (C) and systolic (D) phases. Two-dimensional echocardiogram. Intensive care for circulatory support was initiated; left ventricular dysfunction was transiently improved, but he had rapidly progressive internal and external ophthalmoplegia, flaccid quadriplegia, and ventilation failure due to respiratory muscle paralysis worsened on the Day 2. Electromyography (EMG) with nerve conduction studies of the radial, median, ulnar, and sural nerves showed decreased compound muscle action potential amplitudes and normal conduction velocities. The sensory responses had normal amplitudes and latencies. Repetitive nerve stimulation at 3 Hz shows a decrement of 10%. Rapid repetitive stimulation at 50 Hz shows no increment. Acute inflammatory demyelinating polyneuropathy and myasthenia gravis were excluded by the clinical course, EMG, brain magnetic resonance imaging, and serum autoantibody assays. The tests for toxins in mice using inoculation of the patient's serum and stool revealed BTXA. Trivalent ABE antitoxin on Day 7 was not successful in preventing further worsening. Under intensive monitoring and treatment of the circulatory and respiratory symptoms, the autonomic dysfunction and muscle paralysis gradually ameliorated.

Discussion

To our knowledge, this is the first case of Takotsubo-like myocardial dysfunction in a patient with botulism; however, we believe that this condition has likely also been observed previously in studies on autonomic dysfunction due to botulism (3). Autonomic failure due to botulism had been considered to account for some cases of sudden infant death syndrome (4) as well as arrhythmias and electrocardiographic changes in adults (5). In our case, we hypothesized that the suppression of acetylcholine release in the peripheral ganglia and postganglionic parasympathetic nerves by the botulinum toxins strengthened the postganglionic sympathetic nerve effects, which has norepinephrine as the primary transmitter. When a sympathetic surge occurs, contraction of the resistance vessel rapidly increases the cardiac afterload through α-receptor activation, and hypercontraction of the left ventricle increases mechanical wall stress in the apex through β-receptor activation, resulting in Takotsubo syndrome (2). Furthermore, both the severity of botulism and the cardiovascular disease history of the patient may have contributed to the patient's condition. First, BTXA is longer-acting than other botulinum toxins, particularly botulinum toxin type E (BTXE), which is a more common cause of food-borne botulism (6). Although both BTXA and BTXE degrade the same synaptosomal-associated protein, the protease activity of BTXA is stronger than that of BTXE and acts more rapidly and for longer in presynaptic neurons. Second, the EMG findings showed almost complete denervation of the neuromuscular junctions, suggesting that the patient may have been exposed to a large amount of BTXA (7). Lastly, the patient's medical history likely increased the vulnerability of his circulatory system to autonomic dysfunction. A recent study reported that severe autonomic failure is a significant predictor of mortality in patients undergoing aortic valve replacement and hypothesized that this stems from the abnormal activation of the autonomic cardiac reflex (8). A preclinical study recently showed the retrograde transport of BTXA to upstream neurons (9). Furthermore, patients with cervical dystonia treated with BTXA reported autonomic symptoms, and a quantitative investigation revealed mild subclinical abnormalities in autonomic cardiovascular regulation and cardiopulmonary baroreflex sensitivity in healthy adults (10). We herein report autonomic dysfunction as a major complication of BTXA, particularly in patients with a medical history of cardiovascular disease.

The authors state that they have no Conflict of Interest (COI).
  10 in total

1.  Severe botulism after focal injection of botulinum toxin.

Authors:  N Souayah; H Karim; S S Kamin; J McArdle; S Marcus
Journal:  Neurology       Date:  2006-11-28       Impact factor: 9.910

2.  Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.

Authors:  Ewa Bomba-Warczak; Jason D Vevea; Joel M Brittain; Annette Figueroa-Bernier; William H Tepp; Eric A Johnson; Felix L Yeh; Edwin R Chapman
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

3.  [The electrocardiographic changes in botulin toxinfection].

Authors:  N Puglisi; B Ferlazzo; R Ricciardi
Journal:  Policlinico Prat       Date:  1966-12-12

4.  Severe autonomic failure as a predictor of mortality in aortic valve stenosis.

Authors:  Christine S Zuern; Konstantinos D Rizas; Christian Eick; Marie-Isabel Vogtt; Boris Bigalke; Meinrad Gawaz; Axel Bauer
Journal:  Int J Cardiol       Date:  2014-08-02       Impact factor: 4.164

5.  Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A.

Authors:  D Tiple; S Strano; C Colosimo; G Fabbrini; G Calcagnini; M Prencipe; A Berardelli
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

6.  Infant botulism intoxication and autonomic nervous system dysfunction.

Authors:  Hugues Patural; Philippe Goffaux; Caroline Paricio; Guillaume Emeriaud; Georges Teyssier; Jean-Claude Barthelemy; Vincent Pichot; Frédéric Roche
Journal:  Anaerobe       Date:  2009-03-25       Impact factor: 3.331

Review 7.  Takotsubo cardiomyopathy: a new form of acute, reversible heart failure.

Authors:  Yoshihiro J Akashi; David S Goldstein; Giuseppe Barbaro; Takashi Ueyama
Journal:  Circulation       Date:  2008-12-16       Impact factor: 29.690

8.  Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988.

Authors:  B A Woodruff; P M Griffin; L M McCroskey; J F Smart; R B Wainwright; R G Bryant; L C Hutwagner; C L Hatheway
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

9.  Molecular targets of botulinum toxin at the mammalian neuromuscular junction.

Authors:  Dorothy D Whelchel; Tonia M Brehmer; Paula M Brooks; Neely Darragh; Julie A Coffield
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

10.  Quantitative autonomic testing in the management of botulism.

Authors:  Raffi Topakian; Christoph Heibl; Karl Stieglbauer; Bettina Dreer; Markus Nagl; Peter Knoflach; Franz Thaddäus Aichner
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.